Addex's dipraglurant development in post-stroke recovery supported by data published in brain

Landmark study shows mglu5 receptor negative allosteric modulators (nams) restore lost neurological functions first time mglu5 linked to post - stroke functional recovery ad hoc announcement pursuant to art. 53 lr geneva, switzerland, september 4, 202 3 - addex therapeutics (six and nasdaq: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that data published in brain demonstrating the potential therapeutic role of mglu5 receptor negative allosteric modulators (nams) in facilitating functional recovery following stroke supports the future development of dipraglurant in post-stroke recovery.
ADXN Ratings Summary
ADXN Quant Ranking